SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

SEC Comment Letter 0000000000-24-009070 to GeoVax Labs, Inc. (GOVX)

GeoVax Labs, Inc.
Date: Aug. 8, 2024 · CIK: 0000832489 · Accession: 0000000000-24-009070

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-281310

Date
August 8, 2024
Author
David A. Dodd
Form
UPLOAD
Company
GeoVax Labs, Inc.

Letter

August 8, 2024 David A. Dodd President & Chief Executive Officer GeoVax Labs, Inc. 1900 Lake Park Drive, Suite 380 Smyrna, Georgia 30080 Re:GeoVax Labs, Inc. Registration Statement on Form S-1 Filed August 6, 2024 File No. 333-281310 Dear David A. Dodd: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Chris Edwards at 202-551-6761 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:F. Reid Avett, Esq.

Show Raw Text
August 8, 2024
David A. Dodd
President & Chief Executive Officer
GeoVax Labs, Inc.
1900 Lake Park Drive, Suite 380
Smyrna, Georgia 30080
Re:GeoVax Labs, Inc.
Registration Statement on Form S-1
Filed August 6, 2024
File No. 333-281310
Dear David A. Dodd:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that
the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Chris Edwards at 202-551-6761 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:F. Reid Avett, Esq.